GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis

Kai Xu, Xiang Liu, Bin Wen, Yazhou Liu, Wei Zhang, Xiaolin Hu, Ling Chen, Weijian Hang, Juan ChenFrontiers in Cardiovascular Medicine 2022 · DOI

TL;DR

This study reveals that lipotoxicity in heart cells (cardiomyocytes) leads to a specific type of cell death called ferroptosis, driven by epigenetic changes. The researchers found that a drug, GSK-J4, can protect these cells by reversing these epigenetic alterations, offering a potential therapeutic strategy for metabolic stress-induced heart damage.

What Problem Does This Paper Address?

Modern lifestyles often lead to metabolic disturbances like hyperlipidemia, where excessive free fatty acids can harm cardiomyocytes. While this "lipotoxicity" is known to cause heart problems, the precise mechanisms are still being uncovered. One emerging area of concern is ferroptosis, a cell death pathway linked to lipid peroxidation. The role of ferroptosis in metabolic stress-induced heart injury, particularly in the context of conditions like type 2 diabetes (T2D), remains poorly understood. Furthermore, the paper highlights that even when metabolic issues are managed, the benefits for cardiovascular complications are often limited, suggesting that other factors, like epigenetic modifications, might be at play. This research aims to bridge this gap by investigating the link between lipotoxicity, ferroptosis, and epigenetic regulation in cardiomyocytes.

Methods

The researchers employed a multi-pronged approach:

  • Cell Culture Models: They used AC16 human cardiomyocyte cell lines and primary neonatal rat cardiomyocytes (NRCM) to mimic heart cells and induce injury.
  • Drug Screening: A library of ERS (Endoplasmic Reticulum Stress)-related small molecules was screened to identify potential protective agents against palmitic acid (PA)-induced cell injury.
  • Molecular Biology Techniques:
    • Western Blotting: Used to assess protein levels of key markers, including endoplasmic reticulum stress markers (Bip, ATF4, ATF6), apoptosis markers (caspases), histone modifications (H3K27me3), and specific enzymes like KDM6A and ACSL4.
  • RT-qPCR: To measure mRNA levels of KDM6A and KDM6B.
  • Immunofluorescence and Immunohistochemistry: To visualize and quantify protein localization and expression, particularly H3K27me3 and 4-HNE (a marker of lipid peroxidation).
  • Flow Cytometry: To analyze cell viability, ROS production (using DHE), and apoptosis (Annexin V/PI staining).
  • CCK-8 Assay: A standard method to assess cell viability.
  • LDH Release Assay: To quantify cell damage.
  • Transmission Electron Microscopy (TEM): To examine the ultrastructural changes in mitochondria.
  • C11-BODIPY Staining: A probe to detect lipid peroxidation.
  • ChIP-PCR: To investigate the binding of H3K27me3 to the promoter region of ACSL4.
  • siRNA Knockdown: To specifically reduce the expression of KDM6A and assess its role.
  • Animal Model: DB/DB mice, a model for type 2 diabetes, were used to evaluate the in vivo effects of GSK-J4.
  • Metabolic Assays: Serum and tissue levels of triglyceride, cholesterol, and blood glucose were measured.

Datasets

Not explicitly discussed as distinct datasets. The study utilizes established cell lines (AC16, NRCM) and a well-characterized animal model (DB/DB mice). Experimental data is generated through the described molecular and cellular assays.

Key Insights and Ideas

  • Epigenetic Link to Lipotoxicity: The study strongly suggests that lipotoxicity in cardiomyocytes isn't just about direct damage but also involves epigenetic reprogramming, specifically changes in histone methylation.
  • Ferroptosis as a Key Player: Ferroptosis, a form of regulated cell death driven by lipid peroxidation, is identified as a critical pathway through which lipotoxicity harms cardiomyocytes.
  • GSK-J4 as a Protective Agent: The drug GSK-J4, a KDM6A/6B inhibitor, demonstrates significant cardioprotective effects by counteracting lipotoxicity-induced ferroptosis.
  • H3K27me3 as a Protective Mark: The study highlights that maintaining H3K27me3 methylation levels is crucial for protecting cardiomyocytes from lipotoxicity and ferroptosis.
  • ACSL4 as a Downstream Target: The enzyme ACSL4 is identified as a key mediator, whose expression is upregulated by reduced H3K27me3 and promotes ferroptosis. GSK-J4's protective effect is linked to its ability to suppress ACSL4 expression.
  • GSK-J4's Mechanism of Action: GSK-J4 works by inhibiting KDM6A, which in turn preserves H3K27me3 levels, leading to the suppression of ACSL4 transcription and reduced ferroptosis.

Key Results

  • Palmitic acid (PA) treatment significantly reduced AC16 cell viability and induced endoplasmic reticulum stress (ERS).
  • GSK-J4 demonstrated a dose-dependent protective effect against PA-induced cell injury and reduced LDH release.
  • While GSK-J4 protected cells from PA-induced damage, it did not significantly affect apoptosis markers.
  • PA stimulation upregulated KDM6A expression in cardiomyocytes, while KDM6B expression remained largely unchanged.
  • GSK-J4 treatment dose-dependently upregulated H3K27me3 levels and reversed PA-induced H3K27 demethylation.
  • In DB/DB mice, GSK-J4 treatment showed a trend towards reduced body weight and attenuated cardiomyocyte hypertrophy.
  • GSK-J4 significantly reversed triglyceride accumulation in both DB/DB mice and in vitro cell models.
  • PA treatment increased ROS production and lipid peroxidation, which were attenuated by GSK-J4.
  • PA treatment increased the sensitivity of cardiomyocytes to erastin (a ferroptosis inducer), and GSK-J4 reversed this sensitivity.
  • PA stimulation significantly upregulated ACSL4 expression, and GSK-J4 treatment reversed this upregulation.
  • Overexpression of KDM6A exacerbated PA-induced cardiomyocyte injury and upregulated ACSL4.
  • Silencing KDM6A upregulated H3K27me3, prevented ACSL4 upregulation by PA, and reduced PA-induced cell injury.

Limitations and Future Work

  • Comprehensive H3K27me3 Landscape: The authors acknowledge that they did not obtain a complete genome-wide map of H3K27me3 changes under PA stimulation. Future ChIP-seq analysis could identify more key genes involved in PA-induced lipotoxicity.
  • Role of ERS: While GSK-J4 was screened from an ERS-related library and reduced ERS levels, the precise role of ERS in GSK-J4's protective effect was not fully investigated. Further studies are needed to explore the involvement of key transcriptional factors in ERS.
  • Off-Target Effects of KDM6A Silencing: The authors note that silencing KDM6A might have broader effects beyond ACSL4, potentially impacting other genes and cell viability, as suggested by a slight increase in LDH release. Using GSK-J4 to inhibit KDM6A activity might be a more targeted approach than complete silencing.
  • Further Epigenetic Modifications: The study focuses on H3K27me3. Future research could explore other epigenetic modifications and their roles in diabetes-related cardiovascular complications.
  • Clinical Translation: While GSK-J4 shows promise, further investigation is needed to assess its efficacy and safety in clinical settings for treating hyperlipidemia-induced heart damage.

Summary updated

Abstract

Changes in modern lifestyle provoke a series of metabolic stresses such as hyperlipidemia. Excessive free fatty acids induce cardiomyocyte metabolic reprogramming and rearrangement of the lipid content of cardiomyocyte and promote oxidative stress. As a newly defined lipid peroxidation-related cell death pathway, the role of ferroptosis in metabolic stress-induced cardiomyocyte injury is poorly revealed. Our work indicates that GSK-J4, a histone lysine demethylase 6A/6B dual inhibitor, can alleviate palmitic acid (PA)-induced hypersensitivity to ferroptosis by suppressing H3K27 demethylation. Mechanistically, PA stimulation reduces the H3K27me3 level and hence promotes the expression of ACSL4, a key lipid modulator of ferroptosis. GSK-J4 pretreatment significantly preserves the H3K27me3 level and reduces the ACSL4 level. GSK-J4 also reduces reactive oxygen species to alleviate oxidative stress, which further decreases lipid peroxidation. Taken together, our data suggest that cardiomyocyte undergoes epigenetic reprogramming under metabolic challenges, rearranging lipid content, and sensitizing to ferroptosis. GSK-J4 can be a potential drug for treating hyperlipidemia-induced cardiomyocyte injury by targeting epigenetic modulations.
BibTeX
@inproceedings{xu2022gsk,
  author = {Kai Xu and Xiang Liu and Bin Wen and Yazhou Liu and Wei Zhang and Xiaolin Hu and Ling Chen and Weijian Hang and Juan Chen},
  title = {{GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.907747},
}
Figure